ESMO 2022 | Current treatment options in acral melanoma

Matteo Carlino, FRACP, PhD, University of Sydney and Westmead Hospital, Sydney, Australia, discusses acral melanoma as an unmet need as well as the pathology of this rare form of melanoma. The tumor genetics of acral melanoma can differ to more prevalent types of melanoma, with BRAF mutations being less common. This consequently affects treatment options with immunotherapies such as ipilimumab and nivolumab being not as effective as in other forms of skin cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.